Agnete Fredriksen, Author at Vaccibody.com - Page 4 of 7
-1
archive,paged,author,author-agneteb,author-3,paged-4,author-paged-4,bridge-core-2.4.3,qode-page-transition-enabled,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-25.7,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces pre-clinical data supporting elicitation of strong killer T cell responses (CD8+ T cells) towards cancer neoantigens. The executive management is present at JP Morgan in San...

  Finalization of enrolment in the HPV16 therapeutic vaccine (VB10.16) phase IIa of trial VB C-01. Vaccibody AS announces that enrolment of patients will be finalised in December 2017 for the expansion phase (phase IIa) of its multicentre trial VB C-01. The enrolment goal was 15-20 patients...

Clinical Trial Application for VB10.NEO filed with PEI Vaccibody AS today announced filing of a Clinical Trial Application (CTA) for cancer neoantigen vaccine VB10.NEO with German regulatory authority Paul Ehrlich Institute (PEI). VB10.NEO is a personalized vaccine designed specifically for each patient and the neoantigen mutations...

Vaccibody AS today announced that the cohort review committee as well as the independent data monitoring board have completed their review of the interim analysis of the results from the phase I dosing part of the multicentre trial VB C-01. The two committees recommended continuation...

Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...